Xenoport (f/k/a XNPT)

[surf1944]

4:00PM Xenoport reports favorable metabolism and pharmacokinetics of XP23829, a novel fumaric acid ester, in Phase 1 trial (XNPT) 11.15 -0.15 : Co announced favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics, safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. XP23829 is being developed for the potential treatment of relapsing-remitting multiple sclerosis and/or psoriasis. The trial demonstrated that administration of XP23829 resulted in the expected levels of MMF in the blood. As anticipated, the four formulations produced different PK profiles of MMF, including one formulation that could potentially be dosed two or three times a day and at least one formulation that may be suitable for once-a-day dosing. XP23829 was generally well-tolerated in the trial.